23andMe petitions Fed Circuit for en banc review

DNA testing and analysis company 23andMe has asked the full US Court of Appeals for the Federal Circuit to review an earlier panel decision which held that one of its patents is invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Charpentier CRISPR patent gets good news from Japan

14 December 2023 Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021.

Genetics

Will de-extinct animals be patent eligible in the US?

5 January 2023 Science fiction is becoming science fact but the Alice/Mayo framework throws up some interesting challenges to bringing life back from the dead, explains Brian Hausman of Baker Botts.

Genetics

Gene-editing bill: encouraging innovation or adding complexity?

26 May 2022 UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.

More features

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

23andMe petitions Fed Circuit for en banc review

More on this story

Editor's picks

Editor's picks

More features